HepGene

HepGene is a private U.S. diagnostics and liquid biopsy company focused on early detection, diagnosis, and disease monitoring in liver and metabolic disease. The company's lead program, intelli-HEP, is positioned as a non-invasive liquid biopsy offering for metabolic dysfunction-associated steatotic liver disease, including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. HepGene is part of the IV BioHoldings portfolio and was launched publicly in 2021 after operating in stealth. Its positioning emphasizes objective, blood-based testing across the care continuum, including early detection, confirmatory diagnosis, and progression or reversal monitoring. The company appears to be a platform-style precision diagnostics business rather than a therapeutics developer.